Dr. Jason Mouabbi revisits the patient's Grade 2 hyperglycemia at week 6, when fasting glucose reaches 212 mg/dL.

Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back ...

Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast ...

Dr. Jason Mouabbi discusses additional adverse events that require attention when managing patients with PIK3CA-mutated ...

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively ...

Dr. Jason Mouabbi discusses how available pathway-directed treatment approaches may be differentiated for patients with ...

Dr. Jason Mouabbi discusses strategies for assessing and managing the risk of treatment-related hyperglycemia before ...

Dr. Jason Mouabbi discusses the approach to managing treatment-related hyperglycemia while maintaining cancer treatment for ...

However, applying a conventional age-based testing threshold would have substantially reduced the number of patients identified. Restricting testing to patients diagnosed before age 50 would have ...

Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers. Immune thrombocytopenia (ITP ...

Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer. Theodore Wagener, PhD, founding ...

The addition of carotuximab (ENV-105) to apalutamide (Erleada) significantly improved progression-free survival (PFS) ...